Safety and Pharmacokinetics of RTH258 in Subjects With Age-Related Macular Degeneration

This study has 2 arms with a 1:1 randomization. Randomization will be stratified by Japanese
ethnicity. Half of the subjects in each arm will be of Japanese ethnicity. The other half of
the subjects in each arm will be non-Japanese. Subjects in both arms will have visits
through Day 84.

Inclusion Criteria:

- Provide written informed consent;

- Active choroidal neovascularization (CNV) lesions secondary to AMD that affect the
central subfield in the study eye;

- Best Corrected Visual Acuity (BCVA) ≥ 23 letters in the study eye at Baseline;

- Other protocol-specified inclusion criteria may apply.

Exclusion Criteria:

- Any active ocular infection or inflammation;

- Treatment with aflibercept (EYLEA®), bevacizumab (AVASTIN®), ranibizumab (LUCENTIS®),
pegaptanib (MACUGEN®), or an investigational drug for neovascular AMD prior to
enrollment in the study, as specified in protocol;

- Ocular surgery in the study eye, as specified in protocol;

- Uncontrolled glaucoma in the study eye, as specified in protocol;

- Use of steroids in the study eye, as specified in protocol;

- Medical conditions that may prevent study completion;

- Pregnant or nursing (lactating) women;

- Women of child-bearing potential unless using contraception;

- Uncontrolled blood pressure, as specified in protocol;

- Other protocol-specified exclusion criteria may apply.